Literature DB >> 10766020

RNA processing and human disease.

A V Philips1, T A Cooper.   

Abstract

Gene expression involves multiple regulated steps leading from gene to active protein. Many of these steps involve some aspect of RNA processing. Diseases caused by mutations that directly affect RNA processing are relatively rare compared with mutations that disrupt protein function. The vast majority of diseases of RNA processing result from loss of function of a single gene due to mutations in cis-acting elements required for pre-messenger RNA (mRNA) splicing. However, a few diseases are caused by alterations in the trans-acting factors required for RNA processing and in the vast majority of cases it is the pre-mRNA splicing machinery that is affected. Clearly, alterations that disrupt splicing of pre-mRNAs from large numbers of genes would be lethal at the cellular level. A common theme among these diseases is that only subsets of genes are affected. This is consistent with an emerging view that different subsets of exons require different sets of cis-acting elements and trans-acting factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766020     DOI: 10.1007/PL00000687

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  41 in total

1.  Regulation of alternative splicing by SRrp86 through coactivation and repression of specific SR proteins.

Authors:  Daron C Barnard; Jun Li; Rui Peng; James G Patton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

2.  Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia.

Authors:  Cindy E Jiménez-Ávila; Vanessa Villegas-Ruíz; Marta Zapata-Tarres; Alejandra E Rubio-Portillo; Eleazar I Pérez López; Juan C Zenteno; Sergio Juárez-Méndez
Journal:  Int J Mol Epidemiol Genet       Date:  2018-10-20

3.  ASD: the Alternative Splicing Database.

Authors:  T A Thanaraj; Stefan Stamm; Francis Clark; Jean-Jack Riethoven; Vincent Le Texier; Juha Muilu
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

4.  Genome-wide detection of tissue-specific alternative splicing in the human transcriptome.

Authors:  Qiang Xu; Barmak Modrek; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

5.  Colloquium paper: footprints of nonsentient design inside the human genome.

Authors:  John C Avise
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

6.  Novel exon 11 skipping mutation in a patient with glycogen storage disease type IIId.

Authors:  H Sugie; T Fukuda; M Ito; Y Sugie; T Kojoh; I Nonaka
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

Review 7.  Structural analyses of the pre-mRNA splicing machinery.

Authors:  Lingdi Zhang; Xueni Li; Rui Zhao
Journal:  Protein Sci       Date:  2013-05-08       Impact factor: 6.725

8.  Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Authors:  Fatma Aboulnasr; Ashton Krogman; Rondell P Graham; Nathan W Cummins; Anisha Misra; Enrique Garcia-Rivera; Jeff R Anderson; Sekar Natesampillai; Nicole Kogan; Murali Aravamudan; Zilin Nie; Thomas D Y Chung; Richard Buick; Andrew L Feldman; Rebecca L King; Anne J Novak; Stephen M Ansell; Saad Kenderian; Andrew D Badley
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

9.  Processive phosphorylation of alternative splicing factor/splicing factor 2.

Authors:  Brandon E Aubol; Sutapa Chakrabarti; Jacky Ngo; Jennifer Shaffer; Brad Nolen; Xiang-Dong Fu; Gourisankar Ghosh; Joseph A Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

10.  Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.

Authors:  Hung-Hsi Chen; Yu-Chiuan Wang; Ming-Ji Fann
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.